This is intended for US audiences only.

Actor portrayal.

Welcome to the PURPOSE
Program Investigator Site

Thank you so much for working with us to help evaluate the safety and efficacy of investigational lenacapavir and emtricitabine/​tenofovir alafenamide for PrEP.

What's Happening With PURPOSE 1

Results from the PURPOSE 1 clinical study are now published.
Select one of the sites to visit to see what they found.

See the Gilead statement

on global access planning for
lenacapavir for HIV prevention

See statement

Review the conference presentation

presented at International AIDS
Society (IAS) 2024

Review presentation

Read the published results

of PURPOSE 1 in the New England
Journal of Medicine (NEJM)

Read journal
Actor portrayal.

PURPOSE Presentations and Publications

Here are some links to the presentations and publications about the PURPOSE studies.

PURPOSE 1 - clinicaltrials.gov PURPOSE 2 - clinicaltrials.gov PURPOSE 3 - clinicaltrials.gov PURPOSE 4 - clinicaltrials.gov PURPOSE 5 - clinicaltrials.gov Pregnant and Lactating People in the Lenacapavir for HIV PrEP PURPOSE Program Global Consultation to Plan for Inclusion of Pregnant and Lactating Populations in a Phase 3 PrEP Clinical Trial Inclusion, Experience, and Data: Approaches for Prioritizing the Transgender and Gender-Diverse Voice in a Phase 3 Clinical Trial of Long-Acting PrEP Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP) Update on Gilead's HIV Prevention Trials presented at R4P 2021 Advancing Novel HIV Prevention Strategies, Together: A Scientific and Community Exchange presented at R4P 2021 Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project Sample size calculation for recency assay based clinical trials Using the F/TDF Adherence-Efficacy Relationship to Calculate Background HIV incidence

Community Inclusion Videos

Bringing the trial study sites to where the need is the greatest

Explore a video from Moupali Das, MD, MPH, the Executive Director of HIV Clinical Development at Gilead, as she describes why it was important that PURPOSE 2 add study sites in new locations in the country.

Video length: 1 min.

Inclusion from the start

Learn about how we think "Having everyone at the table makes the science better."

Video length: 1 min.